Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAX | Q07812 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 0.97 |
| ▸ | TP53 | P04637 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.97 |
| ▸ | RAD52 | P43351 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.55 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.53 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PER2 | O15055 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29991749 | 1.00 | BAX (1.00) | BAXMAPTTP53CYP3A4ALOX15 | |
| SCHEMBL610221 | 1.00 | BAX (1.00) | BAXMAPTTP53CYP3A4ALOX15 | |
| SCHEMBL29716701 | 1.00 | BAX (1.00) | BAXMAPTTP53CYP3A4ALOX15 | |
| SCHEMBL29432619 | 1.00 | BAX (1.00) | BAXMAPTTP53CYP3A4ALOX15 | |
| SCHEMBL609455 | 1.00 | BAX (1.00) | BAXMAPTTP53CYP3A4ALOX15 | |
| Hydrochloric Acid SCHEMBL31457408 | 0.99 | MAPT (1.00) | BAXMAPTTP53CYP3A4ALOX15 | |
| Hydrochloric Acid SCHEMBL31457406 | 0.99 | MAPT (1.00) | BAXMAPTTP53CYP3A4ALOX15 | |
| Hydrochloric Acid SCHEMBL21085183 | 0.99 | MAPT (1.00) | BAXMAPTTP53CYP3A4ALOX15 | |
| Hydrochloric Acid SCHEMBL30102393 | 0.99 | MAPT (1.00) | BAXMAPTTP53CYP3A4ALOX15 | |
| Hydrochloric Acid SCHEMBL30102390 | 0.99 | MAPT (1.00) | BAXMAPTTP53CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1237887-B1 | 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS | SERONO LAB (CH) | 2008-06-04 | — | — | EP | claimed |
| EP-1237887-A1 | 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS | Applied Research Systems ARS Holding N.V. (AN) | 2002-09-11 | — | — | EP | claimed |
| WO-2001029028-A1 | 9- (PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-04-26 | — | — | WO | claimed |
| EP-1094063-A1 | 9-(Piperazinylalkyl)carbazoles as Bax-modulators | Applied Research Systems ARS Holding N.V. (AN) | 2001-04-25 | — | — | EP | claimed |
| US-20240268372-A1 | Methods and Compositions for Extending Organ and Tissue Preservation | MASSACHUSETTS GEN HOSPITAL (US) | 2024-08-15 | — | — | US | disclosed |
| EP-4397770-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PreAnalytiX GmbH (CH) | 2024-07-10 | — | — | EP | disclosed |
| US-20240207421-A1 | NERVE TARGETING PEPTIDES AND METHODS OF USE | ALUME BIOSCIENCES INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240207422-A1 | NERVE TARGETING PEPTIDE CONJUGATES AND METHODS OF USE | ALUME BIOSCIENCES INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240124523-A1 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-04-18 | — | — | US | disclosed |
| US-20240091387-A1 | METHODS AND SYSTEMS USING PEPTIDES FOR TARGETING AND MAPPING HUMAN NERVES IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | ALUME BIOSCIENCES INC (US) | 2024-03-21 | — | — | US | disclosed |
| CN-111246873-B | Optimized peptides for targeting human nerves and their use in image guided surgery, diagnosis and therapy delivery | 加利福尼亚大学董事会 | 2024-03-01 | — | — | CN | disclosed |
| EP-3401406-B1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PREANALYTIX GMBH (CH) | 2023-11-29 | — | — | EP | disclosed |
| US-20100035887-A1 | THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-11 | — | — | US | disclosed |
| US-20100035887-A1 | THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-11 | — | — | US | disclosed |
| US-20100016218-A1 | CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| WO-2008152405-A2 | PROTEIN COMPLEXES COMPRISING BH3 PEPTIDES AND VOLTAGE DEPENDENT ANION CHANNEL (VDAC) PEPTIDES AS WELL AS USES THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISEASES | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2008-12-18 | — | — | WO | disclosed |
| EP-1237887-B1 | 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS | SERONO LAB (CH) | 2008-06-04 | — | — | EP | disclosed |
| EP-1237887-A1 | 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS | Applied Research Systems ARS Holding N.V. (AN) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001029028-A1 | 9- (PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-04-26 | — | — | WO | disclosed |
| EP-1094063-A1 | 9-(Piperazinylalkyl)carbazoles as Bax-modulators | Applied Research Systems ARS Holding N.V. (AN) | 2001-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016218-A1 | CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | BAX, BCL2, AIFM1 | BAX 1/4885MAPT 3300/4885TP53 92/4885 |
| US-20100035887-A1 | THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES | TPX2, POLB, POLM | BAX 1339/4885MAPT 4220/4885TP53 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.